Clinical Trial Update: Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

View source ↗

Summary

Expanded access protocol for [123I]mIBG received marketing approval for use in patients with known or suspected neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• [123I]-MIBG (Iodine-123 labeled MIBG (123I-MIBG))

Snippet

Sponsor: GE Healthcare | Conditions: Neuroblastoma | Status: APPROVED_FOR_MARKETING